Methyldopa injection adverse reactions: Difference between revisions
(Created page with "__NOTOC__ {{Methyldopa}} {{CMG}}; {{AE}} {{AK}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = METHYLDOPATE HYDROCHLORIDE INJECTION, SOLUTIO...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
==ADVERSE REACTIONS== | |||
[[Sedation]], usually transient, may occur during the initial period of therapy or whenever the dose is increased. [[Headache]], [[asthenia]], or weakness may be noted as early and transient symptoms. However, significant adverse effects due to methyldopa have been infrequent and this agent usually is well tolerated. | |||
The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity. | |||
'''Cardiovascular:''' Aggravation of [[angina pectoris]], [[congestive heart failure]], prolonged [[carotid sinus hypersensitivity]], [[orthostatic hypotension]] (decrease daily dosage), [[edema ]]or weight gain, [[bradycardia]]. | |||
'''Digestive:''' [[Pancreatitis]], [[colitis]], [[vomiting]], [[diarrhea]], [[sialadenitis]], [[sore ]]or black tongue, [[nausea]], [[constipation]], [[distension]], flatus, dryness of mouth. | |||
'''Endocrine:''' [[Hyperprolactinemia]]. | |||
'''Hematologic:''' [[Bone marrow depression]], [[leukopenia]], [[granulocytopenia]], [[thrombocytopenia]], [[hemolytic anemia]]; positive tests for antinuclear antibody, LE cells, and [[rheumatoid factor]], positive [[Coombs test]]. | |||
'''Hepatic:''' Liver disorders including [[hepatitis]], [[jaundice]], abnormal liver function tests (see [[Methyldopa injection warnings|WARNINGS]]). | |||
'''Hypersensitivity:''' [[Myocarditis]], [[pericarditis]], [[vasculitis]], lupus-like syndrome, drug-related fever, [[eosinophilia]]. | |||
'''Nervous System/Psychiatric:''' [[Parkinsonism]], [[Bell's palsy]], decreased mental acuity, involuntary choreoathetotic movements, symptoms of cerebrovascular insufficiency, psychic disturbances including [[nightmares ]]and reversible mild [[psychoses ]]or [[depression]], [[headache]], [[sedation]], [[asthenia ]]or [[weakness]], [[dizziness]], light-headedness, [[paresthesias]]. | |||
'''Metabolic:''' Rise in [[BUN]]. | |||
'''Musculoskeletal:''' [[Arthralgia]], with or without joint swelling; [[myalgia]]. | |||
'''Respiratory:''' Nasal [[stuffiness]]. | |||
'''Skin:''' [[Toxic epidermal necrolysis]], [[rash]]. | |||
'''Urogenital:''' [[Amenorrhea]], breast enlargement, [[gynecomastia]], [[lactation]], [[impotence]], decreased [[libido]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = METHYLDOPATE HYDROCHLORIDE INJECTION, SOLUTION [AMERICAN REGENT, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5f25053-a9f3-48b9-a412-078f5ee942fd | publisher = | date = | accessdate = 10 March 2014 }}</ref> | |||
Revision as of 17:00, 10 March 2014
| Methyldopa |
|---|
| Methyldopa tablet® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Methyldopa injection® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Methyldopa |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
ADVERSE REACTIONS
Sedation, usually transient, may occur during the initial period of therapy or whenever the dose is increased. Headache, asthenia, or weakness may be noted as early and transient symptoms. However, significant adverse effects due to methyldopa have been infrequent and this agent usually is well tolerated.
The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity.
Cardiovascular: Aggravation of angina pectoris, congestive heart failure, prolonged carotid sinus hypersensitivity, orthostatic hypotension (decrease daily dosage), edema or weight gain, bradycardia.
Digestive: Pancreatitis, colitis, vomiting, diarrhea, sialadenitis, sore or black tongue, nausea, constipation, distension, flatus, dryness of mouth.
Endocrine: Hyperprolactinemia.
Hematologic: Bone marrow depression, leukopenia, granulocytopenia, thrombocytopenia, hemolytic anemia; positive tests for antinuclear antibody, LE cells, and rheumatoid factor, positive Coombs test.
Hepatic: Liver disorders including hepatitis, jaundice, abnormal liver function tests (see WARNINGS).
Hypersensitivity: Myocarditis, pericarditis, vasculitis, lupus-like syndrome, drug-related fever, eosinophilia.
Nervous System/Psychiatric: Parkinsonism, Bell's palsy, decreased mental acuity, involuntary choreoathetotic movements, symptoms of cerebrovascular insufficiency, psychic disturbances including nightmares and reversible mild psychoses or depression, headache, sedation, asthenia or weakness, dizziness, light-headedness, paresthesias.
Metabolic: Rise in BUN.
Musculoskeletal: Arthralgia, with or without joint swelling; myalgia.
Respiratory: Nasal stuffiness.
Skin: Toxic epidermal necrolysis, rash.
Urogenital: Amenorrhea, breast enlargement, gynecomastia, lactation, impotence, decreased libido.[1]
References
- ↑ "METHYLDOPATE HYDROCHLORIDE INJECTION, SOLUTION [AMERICAN REGENT, INC.]". Retrieved 10 March 2014.